ReviewRegenerative therapy2026
Corneal epithelial regenerative medicine: lessons from somatic stem cell therapy toward iPS cell-based regeneration.
Review in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Limbal stem cell deficiency (LSCD) is a severe ocular surface disorder caused by the loss of corneal epithelial stem cell function, and is clinically characterized by corneal neovascularization, opacity, and visual impairment. Conventional corneal transplantation for LSCD is limited by a severe worldwide shortage of donor corneas; even when transplantation is feasible, long-term outcomes remain poor because of postoperative complications such as immunologic rejection and infectious keratitis. To overcome these challenges, corneal epithelial regenerative medicine using somatic stem cells has been developed and translated into clinical practice. Autologous cultivated limbal or oral mucosal epithelial cell sheets have enabled ocular surface reconstruction using patient-derived epithelial cells. Through clinical trials, we demonstrated the efficacy and safety of these approaches. Based on these findings, two pioneering regenerative medicine products were approved in Japan: Nepic, an autologous cultivated limbal epithelial cell sheet, and Ocural, an autologous cultivated oral mucosal epithelial cell sheet. We also contributed to their clinical implementation by establishing criteria for appropriate use, including facility and physician requirements. Following approval, we have been conducting post-marketing surveillance to clarify clinical outcomes and safety in real-world practice. Using these post-marketing and real-world data, we aim to identify prognostic factors and optimize postoperative management for better clinical outcomes. These lessons from somatic stem cell therapy provide an important foundation for the development of next-generation corneal epithelial regenerative medicine, including induced pluripotent stem cell-derived corneal epithelial cell sheets. This review summarizes the historical challenges, clinical translation, implementation, post-marketing evidence, and future perspectives of corneal epithelial regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.